Peginterferon alfa News and Research

RSS
AbbVie's all-oral, interferon-free therapy granted FDA priority review for treatment of GT4 HCV infection

AbbVie's all-oral, interferon-free therapy granted FDA priority review for treatment of GT4 HCV infection

New simeprevir clinical data to be presented at EASL's International Liver Congress 2015

New simeprevir clinical data to be presented at EASL's International Liver Congress 2015

Added benefit of daclatasvir drug not proven for chronic hepatitis C infection

Added benefit of daclatasvir drug not proven for chronic hepatitis C infection

Researchers examine whether new drug offers added benefit for patients with chronic HCV

Researchers examine whether new drug offers added benefit for patients with chronic HCV

Bristol-Myers Squibb launches Daklinza in the UK for treatment of chronic hepatitis C

Bristol-Myers Squibb launches Daklinza in the UK for treatment of chronic hepatitis C

Janssen submits sNDA to FDA for simeprevir in combination with sofosbuvir for treatment of HCV genotype 1 infection

Janssen submits sNDA to FDA for simeprevir in combination with sofosbuvir for treatment of HCV genotype 1 infection

Optimal use of combination therapy achieves best treatment outcomes in patients with CHB

Optimal use of combination therapy achieves best treatment outcomes in patients with CHB

Russian Ministry of Health approves Medivir's simeprevir for chronic hepatitis C genotype 1 infection

Russian Ministry of Health approves Medivir's simeprevir for chronic hepatitis C genotype 1 infection

Merck announces new data from ongoing C-WORTHY Study in HIV/HCV co-infected patients

Merck announces new data from ongoing C-WORTHY Study in HIV/HCV co-infected patients

AbbVie's PEARL-III study meets primary, secondary endpoints in patients with chronic GT1b HCV infection

AbbVie's PEARL-III study meets primary, secondary endpoints in patients with chronic GT1b HCV infection

FDA approves OLYSIO (simeprevir) for treatment of chronic hepatitis C infection

FDA approves OLYSIO (simeprevir) for treatment of chronic hepatitis C infection

Adding danoprevir to treatment regimen for hepatitis C patients leads to high rates of remission

Adding danoprevir to treatment regimen for hepatitis C patients leads to high rates of remission

New injection device delivers optimum treatment dose to hepatitis C patients

New injection device delivers optimum treatment dose to hepatitis C patients

Studies demonstrate encouraging results for new direct-acting antiviral agents

Studies demonstrate encouraging results for new direct-acting antiviral agents

Vertex presents data of telaprevir Phase 3b CONCISE study in people with genotype 1 chronic HCV

Vertex presents data of telaprevir Phase 3b CONCISE study in people with genotype 1 chronic HCV

Data from MK-5172 Phase II study for treatment of HCV genotype 1 infection to be presented at EASL meeting

Data from MK-5172 Phase II study for treatment of HCV genotype 1 infection to be presented at EASL meeting

New data on Merck’s VICTRELIS for chronic HCV to be presented at EASL annual meeting

New data on Merck’s VICTRELIS for chronic HCV to be presented at EASL annual meeting

Hepatitis C and HIV co-infection treatment: an interview with Prof Boecher, Boehringer Ingelheim

Hepatitis C and HIV co-infection treatment: an interview with Prof Boecher, Boehringer Ingelheim

GSK receives FDA approval for PROMACTA to treat thrombocytopenia

GSK receives FDA approval for PROMACTA to treat thrombocytopenia

Weight-based ribavirin undertreats African–American HCV patients

Weight-based ribavirin undertreats African–American HCV patients